LINEBURG


<< . .

 29
( 30)



. . >>

J. Reprod Med 49:8À12.
Schenker JG (1995). Ovarian hyperstimulation syndrome. In (Wallach EE, Zacur HA,
Eds), Reproductive Medicine and Surgery. St. Louis: Mosby Publishing, Chapter 35,
pp. 649À79.
Schenker JG & Polishuk WZ (1976). The role of prostaglandins in ovarian hyperstimula-
tion syndrome. Eur J Obstet Gynecol Reprod Biol 6:47À52.
Serour GI, Aboulghar M, Mansour R et al. (1998). Complications of medically assisted
conception in 3,500 cycles. Fertil Steril 70:638À42.
Shan Tang O, Ng E, Wai Cheng P et al. (2000). Cortical vein thrombosis misinterpreted as
intracranial haemorrhage in severe ovarian hyperstimulation syndrome. Hum Reprod
15:1913À16.
Shapiro AG, Thomas T & Epstein M (1977). Management of hyperstimulation syndrome.
Fertil Steril 28:237À9.
Shiau CS, Chang MY, Chiang CH et al. (2004). Severe ovarian hyperstimulation syndrome
coexisting with a bilateral ectopic pregnancy. Chang Gung Med J. 27:143À7.
Shrivastav P, Nadkarni P & Craft I (1994). Daycare management of severe ovarian
hyperstimulation syndrome avoids hospitalization and morbidity. Hum Reprod
9:812À14.
Southgate HJ, Anderson SK, Lavies NG et al. (1999). Pseudocholinesterase de¬ciency:
a dangerous, unrecognized complication of the ovarian hyperstimulation syndrome.
Ann Clin Biochem 36:256À8.
Splendiani G, Mazzarella B, Tozzo C et al. (1994). Autologous protein reinfusion in severe
ovarian hyperstimulation syndrome. J Am Coll Surg 179:25À8.
225
REFERENCES




Thaler I, Yoffe N, Kaftory J et al. (1981). Treatment of ovarian hyperstimulation
syndrome: the physiologic basis for a modi¬ed approach. Fertil Steril 36:110À13.
Todros T, Carmazzi CM, Bontempo S et al. (1999). Spontaneous ovarian hyperstimula-
tion syndrome and deep vein trombosis in pregnancy: case report. Hum Reprod
14:2245À8.
Tsunoda T, Shibahara H, Hirano Y et al. (2003). Treatment of ovarian hyperstimulation
syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol
17:281À6.
Uhler ML, Budinger GR, Gabram SG & Zinaman J (2001). Perforated duodenal ulcer
associated with ovarian hyperstimulation syndrome: case report. Hum Reprod
16:174À6.
Whelan JG & Vlahos NF (2000). The ovarian hyperstimulation syndrome. Fertil Steril
73:883À96.
Yoshii F, Ooki N, Shinohara Y et al. (1999). Multiple cerebral infarctions associated with
ovarian hyperstimulation syndrome. Neurology 53:225À7.
Zosmer A, Katz Z, Lancet M et al. (1987). Adult respiratory distress syndrome
complicating ovarian hyperstimulation syndrome. Fertil Steril 47:524À6.
INDEX




abdominal paracentesis, ascitic baseline ovarian volume, prediction,
¬‚uid aspiration 210“11 OHSS 124
abdominal pregnancy, surgical treatment benign intracranial hypertension (BIH)
216“17 108“9
ACE inhibitors see angiotensin converting bilateral ectopic pregnancy, surgical treatment
enzyme (ACE) inhibitors, capillary 216“17
permeability biochemical monitoring, patients 202“3
Adult Respiratory Distress Syndrome (ARDS) Body-Mass Index (BMI), incidence,
105 OHSS 14
OHSS treatment 209
albumin administration, intravenous, cabergoline, OHSS treatment 219“20
OHSS prevention 172“7 capillary permeability 47“52
albumin treatment 204 see also vascular permeability
allergy 17“18 ACE inhibitors 50
anesthesia considerations, OHSS ARB 50
treatment 209 endothelin-1 51
angiogenin, roles 65 estrogens 47
angiotensin converting enzyme (ACE) mediators 47“52
inhibitors, capillary progesterone 47“8
permeability 50 prostaglandins 51
angiotensin II receptor blocker (ARB), RAS 48“50
capillary permeability 50 VEGF 55“65
antibiotic treatment 206 von Willebrand factor 51
appendicitis/peritonitis 108 CATSA see continuous autotransfusion system
ARB see angiotensin II receptor blocker (ARB), of ascites (CATSA)
capillary permeability central retinal artery occlusion, vascular
ARDS see Adult Respiratory Distress Syndrome complications, OHSS 101
(ARDS) cerebral infarction
arginine vasopressin secretion, fatal cases, OHSS 93
osmoregulation 45 vascular complications, OHSS 101
aromatase inhibitors, PCOS 137 cerebrovascular thromboses 95
arterial thromboembolism 93 rt-PA 100
arteriolar dilatation, peripheral 43“4 cetrorelix 145
ascites 1, 2 cholestasis, recurrent 106“7
ascitic ¬‚uid aspiration circulatory volume correction 203, 205
abdominal paracentesis 210“11 classi¬cations, OHSS 1“5
analysis, aspirated ascitic ¬‚uid 214 clinical (1999) 7“8
autotransfusion 213 critical OHSS 3, 6“7
indications 210 early OHSS 8
OHSS treatment 210“15 ¬rst (1967) 2“4
peritoneal catheter 211 iatrogenic OHSS 8
peritoneovenous late OHSS 8
shunting 213“15 mild 3“6
transvaginal ultrasound-guided moderate 3“7
aspiration 212“13 modernization (1989) 6
autotransfusion, ascitic ¬‚uid overview 1
aspiration 213 purpose 1



227
228 INDEX




classi¬cations, OHSS (cont.) diuretics 206
reorganization (1978) 4 dopamine 206
severe 3“8 renal compromise 207“8
spontaneous OHSS 8 Doppler blood ¬‚ow velocity 122
clinical characteristics, patients 212 drilling, laparoscopic ovarian 138“43
clinical description, registered OHSS cases 152 duodenal ulcer perforation 107“8
clinical monitoring, patients 202“3 DVT see deep venous thrombosis (DVT)
clomiphene citrate 25
coasting 149“64 ectopic pregnancy, surgical treatment
advantages 149 216“17
Cochrane review 162 electrocautery treatment, PCOS 141
conclusions 164 electrolyte replacement 203
duration 161 embryo transfer, OHSS prevention 145“8
early 159“61 embryos, cryopreservation/replacement
ending 160“1 180“3
estradiol 155 endocrine monitoring, prediction, OHSS
GnRH agonist IVF cycles 155“61 119“20
GnRH antagonist IVF cycles 161“2 endothelial cells
hCG 149“64 roles 67“8
hCG administration 160“1 VEGF 67“8
initiating 159“60 endothelin-1, capillary permeability 51
IVF data 151 erythrocyte aggregation, increased 46
LH 155 estradiol
mechanisms 149“53 coasting 155
non-IVF cycles 154“5 luteal phase support 179
OHSS prevention 149“64 prediction, OHSS 119“20, 125“6
philosophy 149 estrogens
physician attitudes 154 capillary permeability 47
population characteristics 150 hyperestrogenism 96“7
problems 162“4 etiology of infertility, incidence, OHSS 14
success rate 162 extrapulmonary features, OHSS 103
Cochrane review
coasting 162 factor V leiden mutation, spontaneous
OHSS prevention 176 OHSS 98“9
combined approach, OHSS familial gestational spontaneous OHSS 84
prevention 184 familial OHSS 31
complications, OHSS 92“112 family history, thromboembolic
fatal cases 92“3 complications 100
vascular complications 94“6 fatal cases, OHSS 92“3
conception cycles 29“30 cerebral infarction 93
duration, OHSS 29“30 hepato-renal failure 93
frequency, OHSS 29 hMG 93
continuous autotransfusion system of ascites pregnant mare serum gonadotrophins 92
(CATSA) 214 respiratory insuf¬ciency 93
cryopreservation/replacement, embryos, OHSS febrile morbidity 109, 110
prevention 180“3 ¬broblast growth factor-4, VEGF 54
cycles, OHSS, stimulation characteristics 21 follicle stimulating hormone (FSH)
cysts, follicular 1, 215 function 79
cysts, ruptured, surgical granulosa cell responses 133
treatment 215“16 long-acting recombinant 24
cytokines low dose 132“5
prediction, OHSS 122“3 molecule model 81
VEGF 54, 59 oogenesis 82“3
PCOS 132“5
DDAVP see desmopressin (DDAVP) puri¬ed urinary 21“2
deep venous thrombosis (DVT) 100 recombinant 19, 22“3, 95
recombinant FSH 95 roles 82“3
spontaneous OHSS 33 sequence 81
desmopressin (DDAVP) 51 structure 79
229
INDEX




follicle stimulating hormone (FSH) OHSS prevention 143“5
receptor 79“90 VEGF 61
function 79 gonadotrophin-releasing hormone (GnRH),
gene 80 native, ovulation trigger 172
ovarian response 82“3 gonadotrophins
signal transduction 82 development 18“19
structure 79 ¬xed dose 24
follicle stimulating hormone (FSH) human menopausal (hMG) 20“1
receptor mutations 83“7 human pituitary 20
chorionic gonadotrophin sensitive 85 low dose 132“6
effects 87 OHSS prevention 136
hCG sensitivity 85“6 ovarian stimulation protocol 18“21, 24
iatrogenic OHSS 87“8 ovulation induction 134
location 87 PCOS 132“6
mechanisms 87 pregnant mare serum 19, 92
naturally occurring 83“7 preparations, characteristics 20
and OHSS 84“7 structure 80
spontaneous OHSS 83“8 VEGF 58“9
symptoms severity prediction granulosa cell responses
88“9 FSH 133
TSH sensitivity 85“6 PCOS 133
follicular aspiration
hCG 178“9 hCG see human chorionic gonadotrophin
OHSS prevention 178“9 (hCG)
oocyte retrieval 178 hemoconcentration 96“101
follicular cysts 1, 215 hypercoagulable state 96“100
follicular ¬‚uid, VEGF 61 hyperestrogenism 96“7
follicular monitoring by ultrasound mechanical factors 96
baseline ovarian volume 124 plasma hemostatic markers 97“8
follicles, number/size 124 thrombophilia 98“100
necklace sign 124 thromboses 96
prediction, OHSS 124“6 vacular reactivity impairment 101
forearm amputation, vascular complications, hepato-renal failure, fatal cases, OHSS 93
OHSS 101 HES see hydroxyethyl starch (HES)
FSH see follicle stimulating hormone (FSH) hMG see human menopausal gonadotrophins
receptor mutations (hMG)
hospitalization of patients
gastrointestinal complications 107 clinical characteristics, patients 212
gastrointestinal surgery, OHSS treatment OHSS treatment 201“2
217 human chorionic gonadotrophin (hCG) 11“12
gene expression, VEGF 53“4 alternatives 165“72
genetics 79“90 coasting 149“64
glucocorticoid administration, OHSS dosage, OHSS prevention 164“5
prevention 177 follicular aspiration 178“9
GnRH see gonadotrophin-releasing hormone luteal phase support 179
(GnRH) antagonist luteal, role 28
gonadotroph adenomas, spontaneous OHSS prevention 148“72
OHSS 69 recombinant, OHSS prevention 165“72
gonadotrophin-releasing hormone (GnRH) sensitivity, FSH receptor mutations
agonist 11, 25“6 85“6
effectiveness 167 spontaneous OHSS 30
cf. GnRH antagonist 144 VEGF 58
OHSS prevention 168, 181“3 withholding 148
ovulation trigger 165“9 human menopausal gonadotrophins (hMG)
gonadotrophin-releasing hormone (GnRH) fatal cases, OHSS 93
antagonist 26“8 ovarian stimulation protocol 11“12, 20“1
cf. GnRH agonist 144 hydroxyethyl starch (HES)
long agonist protocol alternative administration, OHSS prevention 176“7
143“5 circulatory volume correction 203, 205
230 INDEX




hypercoagulable state, hemoconcentration intra-arterial recombinant tissue
96“100 plasminogen activator (rt-PA),
hyperestrogenism, hemoconcentration thromboembolism 100
96“7 invasive hemodynamic monitoring 208
hyperinsulinism 16“17 isolated pleural effusion 104
hyperoxia, VEGF 54 IVF see in-vitro fertilization (IVF)
hypertension, benign intracranial 108“9
ketoconazole, PCOS 137
hyperthyroidism, recurrent gestational
89“90
laparoscopic ovarian drilling, PCOS 138“43
hypogammaglobulinemia 46
laser treatment, PCOS 142
hypothyroidism 31“3
LH see luteinizing hormone (LH)
hypoxia, VEGF 54
liver abnormalities, etiopathology 106
liver dysfunction 106
iatrogenic OHSS long-acting recombinant FSH 24
chonological development 89 long agonist protocol alternative, GnRH
classi¬cations, OHSS 8 antagonist 143“5
development 89 luteal hCG, role 28
FSH receptor mutations 87“8 luteal phase support 28
symptoms severity prediction 88“9 estradiol 179
ICAM see intercellular adhesion hCG 179
molecule (ICAM), roles OHSS prevention 179“80
immune system, roles 66“7 progesterone 179“80
immunoglobulin replacement therapy 206 luteinizing hormone (LH)
immunoglobulins 46 coasting 155
in-vitro fertilization (IVF) ovulation trigger 169“71
impact, OHSS development 10“12
natural cycle, OHSS prevention 145 macromolecules administration, OHSS
incidence, OHSS 10“13 prevention 172“80
age 13“14 medical treatment, OHSS 203“7
BMI 14 mesenteric artery occlusion in OHSS 107
etiology of infertility 14 mesothelial cells proliferation 108
factors in¬‚uencing 13“14 metformin
indomethacin 207 insulin resistance 137
infective organisms, OHSS 111 ovulation induction 137
information for patients, OHSS 126 PCOS 137
inhibin-B, prediction, OHSS 124 monitoring
insulin, hyperinsulinism 16“17 biochemical
insulin-like growth factor-1, VEGF 54 clinical 202“3
insulin resistance, metformin 137 endocrine 119“20
intensive care follicular 124“6
ARDS 209 invasive hemodynamic 208
OHSS treatment 207“9 patients 202“3
renal compromise 207“9 ultrasound, follicular monitoring 124“6
thromboembolic complications 209 mortality see hepato-renal failure, fatal cases,
intercellular adhesion molecule (ICAM), roles OHSS
65“6 mRNA expression, VEGF
interleukin-1b, VEGF 54 human luteinized granulosa cells 56“7
interleukin-2 rat and primate ovary 56
roles 62“3 mutations
VEGF 61 see also follicle stimulating hormone (FSH)
interleukin-6 receptor mutations
roles 63“4 factor V leiden mutation 99
VEGF 54, 61 thyrotropin receptor mutation 89“90
interleukin-8, roles 64 myocardial infarction, vascular complications,
interleukin-10 OHSS 101“2
roles 64“5
VEGF 54 natural cycle IVF, OHSS prevention 145
interleukin-18, roles 64 non-steroidal anti-in¬‚ammatory drugs
interleukins, roles 62“4 (NSAIDS) 51
231
INDEX




novel medical treatment, OHSS treatment personal history, thromboembolic
218“20 complications 100
NSAIDS see non-steroidal anti-in¬‚ammatory plasma hemostatic markers,
drugs (NSAIDS) hemoconcentration 97“8
platelet derived growth factor,
obstetric complications 109“12 VEGF 54
octreotide, OHSS prevention 138 pleural effusion
oocyte retrieval, OHSS prevention 183 isolated 104
oocytes, in vitro maturation 146 treatment 208“15
oogenesis, FSH 82“3 unilateral, respiratory complications,
osmoregulation 44“6 OHSS 102“5
arginine vasopressin secretion 45 pleurocentesis 208“9
outpatient management, OHSS treatment polycystic ovarian syndrome
200“2 (PCOS) 14“17
ovarian cyst formation, VEGF 55 aromatase inhibitors 137
ovarian drilling, laparoscopic 138“43 biological data 147
ovarian resistance, prediction, OHSS 125 birth reports 147
ovarian response, FSH receptor 82“3 characteristics 14, 15
ovarian stimulation protocol 18“25 clinical manifestations 17
¬xed dose gonadotrophins 24 electrocautery treatment 141
gonadotrophins 18“21, 24 FSH, low dose 132“5
human menopausal gonadotrophins gonadotrophins 132“6
(hMG) 11“12, 20“1 granulosa cell responses 133
human pituitary gonadotrophins 20 hyperinsulinism 16“17
long-acting recombinant FSH 24 ketoconazole 137
pregnant mare serum laparoscopic ovarian
gonadotrophins 19 drilling 138“43
puri¬ed urinary FSH 21“2 laser treatment 142
recombinant FSH 22“4 lifestyle modi¬cation 132
ovarian torsion, surgical treatment 216 metformin 137
ovarian volume, prediction, OHSS 124 OHSS prevention 131“8
ovulation induction 10“12 ovulation induction 131
gonadotrophins 134 pathophysiology 15, 16
metformin 137 prediction, OHSS 119“26
PCOS 131 cytokines 122“3
step-down/step-up protocols 133“5 endocrine monitoring 119“20
estradiol 119“20, 125“6
pathophysiology, OHSS 43, 44 follicular monitoring by ultrasound
patients 124“6
see also treatment, OHSS genetic prediction 125
clinical characteristics 212 inhibin-B 124
information for 126 ovarian resistance 125
monitoring 202“3 ovarian volume 124
outpatient management 200“2 risk factors 125“6
risk assessment 130 serum estradiol 125“6
PCOS see polycystic ovarian syndrome ultrasound, follicular monitoring 124“6
(PCOS) VEGF 120“2
pentoxifylline, OHSS prevention 138 von Willebrand factor 123
pericardiocentesis 209 pregnancy complications 109“12
perinatal complications, OHSS 112 abdominal pregnancy 216“17
peripheral arteriolar dilatation 43“4 bilateral ectopic pregnancy 216“17
peritoneal catheter, ascitic ¬‚uid ectopic pregnancy 216“17
aspiration 211 pregnancy incidence, OHSS
peritoneal ¬‚uid, source 46“7 pregnancy termination 217
peritoneovenous shunting, ascitic ¬‚uid pregnant mare serum gonadotrophins
aspiration 213“15 19, 92
peritonitis/appendicitis 108 prevention, OHSS 130“84
permeability see capillary permeability; vascular coasting 149“64
permeability combined approach 184
232 INDEX




prevention, OHSS (cont.) respiratory complications, OHSS 102“5
cryopreservation/replacement, embryos ARDS 105
180“3 unilateral pleural effusion 102“5
embryo transfer 145“8 respiratory insuf¬ciency, fatal cases,
GnRH antagonist as an alternative to the OHSS 93
long agonist protocol 143“5 risk, OHSS
gonadotrophins 136 characterization of patients 13
hCG 148“72 patient risk assessment 130
hCG dosage 164“5 severe 13
hCG, recombinant 165“72 rt-PA see intra-arterial recombinant tissue
IVF, natural cycle 145 plasminogen activator (rt-PA),
laparoscopic ovarian drilling in PCOS thromboembolism
patients 138“43 ruptured cysts, surgical treatment 215“16
macromolecules administration 172“80
natural cycle IVF 145 screening, thrombophilia 99
octreotide 138 secondary prevention, OHSS 131, 148“84
oocyte retrieval 183 selectins, roles 65“6
PCOS 131“8 selective oocyte retrieval, OHSS prevention 183
pentoxifylline 138 serum estradiol, prediction, OHSS 119“20,
primary prevention, OHSS 130“48 125“6
protocol 146“8 single embryo transfer, OHSS prevention
recombinant hCG 165“72 145“8
secondary prevention, OHSS 131, spontaneous OHSS 30“2
148“84 chonological development 89
selective oocyte retrieval 183 classi¬cations, OHSS 8
single embryo transfer 145“8 development 89
stimulation protocols 131“8 DVT 33
VEGF receptor blockade 184 factor V leiden mutation 98“9
primary prevention, OHSS 130“48 familial gestational 84
progesterone FSH receptor mutations 83“8

<< . .

 29
( 30)



. . >>

Copyright Design by: Sunlight webdesign